ReviewJournal of thoracic disease2020
The public health response to the COVID-19 outbreak in mainland China: a narrative review.
Review in Journal of thoracic disease, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Epidemiological characteristics of childhood infectious diseases at Qingyang maternal and child health care hospital during the COVID-19 pandemic and the post-pandemic period.Frontiers in pediatrics · 2026Article
- Impact of COVID-19 on new pharmacotherapy for insomnia: A matched cohort study using the national insurance claims database in Japan.PloS one · 2026Article
- Fast-tracking international health regulations in Sierra Leone through implementation of the third edition of Integrated Disease Surveillance and Response (IDSR) guidelines during COVID-19 pandemic, 2019-2021: a mixed methods study.BMC health services research · 2025Article
- Epidemiological characteristics of respiratory tract infections during and after the pandemic of COVID-19 from 2021 - 2023 in Shenzhen, southern China.BMC public health · 2025Article
- Assessing the evolution of infectious disease preparedness among a province with poor economy in China in the wake of COVID-19.Frontiers in public health · 2025Article
- Advancing the Management of Long COVID by Integrating into Health Informatics Domain: Current and Future Perspectives.International journal of environmental research and public health · 2023Review
- Public Health Measures and the Control of COVID-19 in China.Clinical reviews in allergy & immunology · 2023Review
- Waste management model for COVID-19: recommendations for future threats.International journal of environmental science and technology : IJEST · 2023Article
- Article
- Place of distancing measures in containing epidemics: a scoping review.The Libyan journal of medicine · 2022Article
- Pregnant under quarantine: Women's agency and access to medical care under Wuhan's COVID-19 lockdown.SSM. Qualitative research in health · 2022Article
- Health Services Utilization in China during the COVID-19 Pandemic: Results from a Large-Scale Online Survey.International journal of environmental research and public health · 2022Article
- Implementation and challenges to preventing the re-establishment of malaria in China in the COVID-19 era.Globalization and health · 2022Article
- Dynamics of Viral Infection and Evolution of SARS-CoV-2 Variants in the Calabria Area of Southern Italy.Frontiers in microbiology · 2022Article
- Application of artificial intelligence in COVID-19 medical area: a systematic review.Journal of thoracic disease · 2021Review
- Article
- Association between coronavirus disease 2019 (COVID-19) and long-term exposure to air pollution: Evidence from the first epidemic wave in China.Environmental pollution (Barking, Essex : 1987) · 2021Article
- The impact of the COVID-19 pandemic on health services utilization in China: Time-series analyses for 2016-2020.The Lancet regional health. Western Pacific · 2021Article
- Transmission of SARS-CoV-2 before and after symptom onset: impact of nonpharmaceutical interventions in China.European journal of epidemiology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused nations to adopt unprecedented control measures in order to curb its spread. As the first nation to respond, China's aggressive control measures appeared to have been effective in suppressing the first wave and keeping new cases under control. Here, we provide the historical context and details of China's public health response to COVID-19. We highlight the lessons and impact of the 2002-2003 SARS outbreak, which demonstrated the importance of transparency, surveillance and testing laboratories during an outbreak. We provide an overview of China's response strategy that was based on the principles of early detection, isolation, management and treatment and involved not only the large-scale coordination of multiple governmental bodies but also grass-root community participation throughout the country. These community-based organizations conducted active surveillance for febrile cases and provided support for those in quarantine and communities in lockdown. Importantly, these broader measures were supported by digital technology, including the extensive use of internet-based platforms and mobile applications (APPs). While there have been no significant increases in case numbers since April, there is still much concern over a second wave, considering the resumption of work and school, the lifting of travel restrictions and the outbreaks occurring globally. Control measures has since been implemented by provincial authorities, which includes continued surveillance and rapid testing. Although China's strict control measures may not suit every nation, the principles of early detection and isolation continue to hold true and have been a cornerstone of the initial and ongoing response to the COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.